Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078001" target="_blank" >RIV/00209805:_____/18:00078001 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00105319
Result on the web
<a href="https://dx.doi.org/10.1007/s00262-018-2166-4" target="_blank" >https://dx.doi.org/10.1007/s00262-018-2166-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00262-018-2166-4" target="_blank" >10.1007/s00262-018-2166-4</a>
Alternative languages
Result language
angličtina
Original language name
Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment
Original language description
Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer immunology, immunotherapy
ISSN
0340-7004
e-ISSN
—
Volume of the periodical
67
Issue of the periodical within the volume
12
Country of publishing house
DE - GERMANY
Number of pages
11
Pages from-to
1919-1929
UT code for WoS article
000450811900011
EID of the result in the Scopus database
2-s2.0-85046774605